Mechanism and Therapy
Transcription
Mechanism and Therapy
Partnering Event Session: Mechanisms and Therapy, including cell therapy CHARLES S. IRVING Charles S. Irving, PhD, CEO +972-54-524-5677 [email protected] Topic: Mechanisms and therapies, including cell therapy Subject of interest: Therapeutic cells derived from human embryonic stem cell (hESC) for the treatment of neural and retinal degenerative diseases Core Technology: • Methods for neural and retinal cell differentiation and transplantation • Translation of research methods to cGMP production • Use of clinical grade hESCs as starting material • Cell characterization and animal models • Safety testing of hESC derived cells No existing Israel – Canada partnerships yet Cell Cure Neurosciences Team: CSO : Prof. Benjamin Reubinoff, Head of hESC Research Center, Hadassah Consultants: Prof. Tamir Ben Hur, Head Neurology, Hadassah Prof. Eyal Banin, Head Macular Degeneration Group, Hadassah Company Core Team working with Hadassah experts Accomplishments: - Mid-brain dopaminergic neural progenitor cells for Parkinson’s disease - Oligodendrocyte progenitor cells for demyelinating diseases• - Retinal pigmented epithelium (RPE) cells for dry age-related macular degeneration• - License Option Agreement with Teva for OpRegen® Modes and Areas of Collaborations: - Consortiums, tech transfers (NDAs, MTAs, licenses) - Disease targets and platform technologies cell lines and purification methods, scaffolds, devices of delivery, assays of biodistribution microfluidic systems for point-of-care cell concentration and resuspension ADRIAN HAREL BrainStorm Cell Therapeutics Ltd. 12 Bazel St., POB 10019 Kiryat Aryeh, Petach Tikva, Israel 49001 Tel: (972) 3.923.6384, Fax: (972) 3.923.6385 E-mail: [email protected] Web: www.brainstorm-cell.com Stem Cell Therapy for ALS NurOwn ™ autologous adult stem cells transplanted into patients Major accomplishments: Brainstorm was granted FDA orphan drug designation for NurOwn™ as a candidate stem cell therapy for ALS. Brainstorm obtained Israeli Ministry of Health clearance for a clinical trial for its differentiated stem cell therapy. Phase I/II trial for treatment of ALS initiated the at the Hadassah University Medical Center, Jerusalem in June 2011. No existing partnership between Brainstorm and Canada 6 NurOwn™ Therapy Step by Step Stem cells are harvested from the Bone marrow, and Mesenchymal Stromal cells (MSC) isolated from the total bone marrow population and then expanded and induced to differentiate into MSC-NTF cells. The cells are then transplanted back into the patient at the site of damage (into the brain for Parkinson’s disease, the muscles or Spinal cord for ALS and Spinal cord Injury). 7 Proposed Research Projects Animal model for motor-neuron degeneration Development of new animal models for neuron degeneration allowing to investigate the effect of stem cell transplantation Production process in Serum-Free Medium Development of a production process based on Serum-Free Medium (SFM) devoid of human-derived components, suitable for use in any worldwide location in which BrainStorm may wish to establish its production process. Neuroprotection cell-based assays Development of functional in-vitro cell based assays in which Neuroprotection of Brainstorm’s NTF secreting cells can be evaluated. 8 MICHAEL G. FEHLINGS Name: Michael G. Fehlings MD PhD; University of Toronto Neuroscience Program Contact: Tel: 416-603-5072; email: [email protected] • • • • Topic: Mechanisms and Therapy (Cell therapy) Subject of interest: Neural stem cells as a strategy for remyelination of CNS white matter injury/disease Core technology: Neural stem cells; non-viral induced pluripotent stem cells About the group and major accomplishments: – Collaborations with NeuroDevNet NCE – Multidisciplinary SCI-NET team which is focused on combining neural stem cells, bioengineered strategies and neurosurgical strategies for the treatment of brain and spinal cord injury (team is led by Michael Fehlings and includes Derek van der Kooy, Molly Shoichet, Andras Nagy, Cindi Morshead, Charles Tator) • Existing partnership between Israel and Canada– Some initial linkages with Michal Schwartz (Weitzman Institute) • Suggestions for mode of collaboration (for example consortium)– Opportunities for collaboration through NeuroDevNet NCE – Through Ontario Brain Institute/University of Toronto Neuroscience Program Schematic of Fibroblast to Axonal Remyelination: The Promise of Induced Pluripotent Stem Cells iPS cell FRIDA GRYNSPAN Mechanisms and Therapy, including cell therapy Subject of Interest: Development of Cell-based Therapeutics. About the Company: Pluristem Therapeutics Inc. is a leading developer of placentabased cell therapies. The company owns a patented PLX (PLacental eXpanded) cells drug delivery platform. Pluristem has a strong patent portfolio, GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. The R&D team include 10 PhD and 2 MD covering the fields of cellular therapy, immunology , and angiogenesis. Core technology: The company has developed and owns a unique cell manufacturing technology. The cell product(s) release a cocktail of therapeutic proteins in response to a host of local and systemic ischemic and inflammatory signals. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching prior to administration. Major accomplishments: PLX-PAD, has successfully completed 2 dose escalation Phase I clinical trials totaling 27 patients suffering from critical limb ischemia (CLI) in Germany and the USA. The product was found to be safe and potentially effective for the treatment of end stage peripheral artery disease. Major Accomplishments cont.: Pluristem received an approval for its pivotal Phase II/III study in critical limb ischemia (CLI) from both the EMEA and the FDA. Pluristem and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charité - University of Medicine in Berlin, announced the results of a preclinical study demonstrating significant improvement in the recovery of muscle function, when compared to controls, following the local administration of PLX cells in a muscle injury mice model. Pluristem's has entered into an exclusive out-license agreement with United Therapeutics Corporation (NasdaqGS: UTHR) for the use of Pluristem’s PLX to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH). Pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain, when administered locally, and in inflammatory bowel disease, MS and stroke, when administered systemically. Furthermore we are currently studying the effect of iv infusion of PLX cells on the BM after exposure to semi lethal doses of radiation. Possible modes of collaboration The Company is interested in exploring through collaborative efforts additional indications including, but not limited to, MS, Parkinson and Alzheimer’s disease. The aim of the Company is to check the therapeutic effect of the cells at the basic research and preclinical levels as to develop clinically relevant programs that will lead to clinical trials in the after mentioned indications. SHULAMIT LEVENBERG Prof. Shulamit Levenberg Tissue Engineering Lab Technion- Israel Institute of Technology, Department of Biomedical Engineering +972(4)8294810; [email protected] • TOPIC: Mechanisms and Therapy, including cell therapy • SUBJECT OF INTEREST: Tissue Engineering Strategies for Spinal Cord Repair Aims: 1) Develop a clinically relevant implantable construct using cells seeded on a biodegradable scaffold; 2) Test the ability of this construct to promote neural regeneration and functional recovery following implantation into a mouse model of spinal cord injury. • CORE TECHNOLOGY: Vascularization of engineered tissues; Stem cell differentiation on 3D scaffolds; Controlling stem cell microenvironments Lesman. et al, Submitted, 2011 Levy et al .Tissue Eng. 2009 Levenberg, et al Blood 2007, Levenberg et al , J. Vascular Res, 2005 Levenberg et al, Nat Biotech, 2005 Caspi et al . Circ Res, 2007 Lesman et al. Tissue Eng 2010 Lesman et al. Ann N Y A S. 2010 Lesman et al. Biotech Bioeng, 2010 Olfactory bulb cells grown on PLLA/PLGA scaffolds p75NTR Phalloidin Heart Muscle scaffold Merged X 1.6 Confocal Imaging of Vascularization Network on PLLA/PLGA Scaffold and its integartion with the host vasculature EXISTING PARTNERSHIP BETWEEN ISRAEL AND CANADA: Prof. Charles Tator (Toronto Western Research Institute, Canada), a world leader in spinal cord regeneration with extensive experience in experimental SCI models, stem cell transplantation, and spinal cord ischemia. He has over 270 peerreviewed articles, and many prestigious awards. • SUGGESTIONS FOR MODE OF COLLABORATION: Development and characterization of the cellular construct will be performed in Prof. Levenberg’s lab. The potential of the cellular construct to promote functional neural regeneration will be tested in animal models in collaboration with other groups. Nature Biotech, 2005, Circulation Res. 2007 Tissue Eng. Rev. 2009, Tissue Eng. 2010, Ann NY Acad Sci. 2010 ARIE DAGAN REUVEN OR Dr. Arie Dagan [email protected] 052-2462593 Prof. Reuven Or [email protected] 02-6776561 Topic: Cell therapy Subject of interest: Core technology: We develop an innovative homogenic culture of human neural cell lines derived from UCB by adding our novel synthetic sphingolipid analogues combined with differentiation and proliferation factors at different developmental stages of cell differentiation. The Bone Marrow Transplantation Department at Hadassah Hebrew University Medical Center operates as a national center for bone marrow transplantation and stem-cell-based medicine. * The department uses stem cells from various sources including bone marrow, peripheral blood, umbilical cord blood and the placenta. * The department treats patients of all ages who are in need of bone marrow transplantation. Treatment is provided within an integrated setting including both inpatient and ambulatory treatment centers. * The department includes a laboratory complex which is affiliated with the Hebrew University’s School of Medicine. * The laboratory's team, headed by Prof. Reuven Or, includes a number of highly respected and accomplished scientists who conduct advanced research with a focus on biological mechanisms of stem cells derived from cord blood and bone marrow. The biochemistry laboratory at the Hebrew University specializes in the development of novel synthetic sphingolipid analogues for manipulation of sphingolipid metabolism and cell regulation. We are developing inhibitors of enzymes participating in the sphingolipid cascade as novel agents in cancer chemotherapy. Another research focuses on sphingolipid signaling, in particular Ceramide and Sphingosine-1-Phosphate, in the acute pathophysiology of CNS injury, neurodegenerative diseases and repair mechanisms. GFAPFITC MAP2FITC Staining of Neuronal markers in human neural cell line derived from umbilical cord blood PHILIP LAZAROVICI HADAR ARIEN-ZAKAY The Hebrew University of Jerusalem Institute for Drug Research, School of Pharmacy Laboratory of NeuroPharmacology Prof. Philip Lazarovici, [email protected], 972-2-6758729 Dr. Hadar Arien-Zakay, Laboratory of Brain Trauma Prof. Esther Shohami [email protected], 972-2-6757513 Sheba Medical Center Division of Hemathology, BMT&CBB Prof. Arnon Nagler [email protected] 972-3-5305830 [email protected], 972-2-6757767 Topic - Mechanisms and Therapy, including cell therapy Subject of interest – Mechanisms of stem cells therapeutic effect in brain ischemia Core technology – Stem cells, ischemic and neuroprotection in vitro and in vivo validated pharmacological models About the group and major accomplishments – ** Accelerating drug discovery towards licensing in neurology and regenerative medicine. ** Unique expertise in molecular pharmacology of growth factors and stem cells for novel lead compounds and cell therapy. ** Over 20 years of pharmacological contracts with companies including Fidia Italy; USA: McNeil Pharmaceutical, Promega; Japan: Kyowa Hakko Kogyo; Israel: Alomone Labs, Sigma, Compugene, D-Pharm, Given Imaging, Teva, Rafa, Pluristem. Existing partnership between Israel and Canada – Prof. David Kaplan and Prof. Freda Miller, Hospital for Sick Children MaRs Center, University of Toronto, Toronto; Prof. Uri Saragovi, Dep. Pharmacology, McGill University, Montreal Suggestions for mode of collaboration – contract services, licensing, consortium (Yissum) Regenerative medicine: mechanisms of stem cell therapeutic effects Delivery systems Tissue engineered scaffolds for brain implantation Non-invasive far near infra-red imaging Proteomics and immune assays Traumatic ischemic brain injury mice model (wild type, transgenic and knock out) Neurovascular ischemic pharmacological models in vitro (OGD) (Primary, cloned and stem cell derived cortical, sensory and sympathetic neurons, Brain capillary endothelium, Transformed neuronal and glial cells) Neurotrophins (NGF, BDNF, GDNF) Angiogenic growth factors (VEGF, FGF-2) Antioxidants (Glutathione, Carnosine, Homocarnosine) Human cord blood and derived neuroprotective progenitors Adult skin neuronal stem cells ERAN PERLSON Molecular Mechanisms of Axonal Transportand of Neurodegeneration Eran Perlson, TAU Medical School Department of Physiology and Pharmacology • Alterations in axonal transport leads to neurodegenerative diseases • Dynein play a role both in long distance signaling and in receptors clustering and targeting for example in the neuromuscular junction In vitro microfluidic platform with motor neuron cell bodies on one side and muscle cells on the other, creates a powerful system to study axonal transport and neuromuscular junction maintenance mechanisms Knowledge / Control over Components Complexity From in vitro to In vivo model systems Our current efforts are focused on studying molecular mechanisms of: • Axonal transport • Communication between the neuron and its environments • Retrograde signaling and cell survival • Synapse stability and maintenance • RNA transport in health and disease • Receptors spatial targeting • Virus trafficking • Membrane dynamics • Microfluidic system, single molecule and nanotechnology TONY CRUZ Tony Cruz Transition Therapeutics Inc. 416-260-7770, [email protected] • Topic: Mechanisms and Therapy • Subject of Interest: CNS drug development • About Transition – Clinical and preclinical stage drug candidates in CNS, inflammatory and metabolic indications – Expertise in advancing preclinical drug candidates to the clinic – Expertise in clinical trials in Alzheimer’s disease, multiple sclerosis, traumatic brain injury and other non-CNS indications – Strategic partnerships with large pharma (Elan and Eli Lilly) – Listed on NASDAQ (TTHI) and TSX (TTH) • Leveraging resources and expertise between Israel and Canada for novel CNS drug development LEVERAGE OF RESOURCES AND EXPERTISE BETWEEN ISRAEL AND CANADA FOR NOVEL CNS DRUG DEVELOPMENT 1. Establish a system to evaluate and rapidly fund innovation with clear and short-term goals to validate technology towards product development and partnerships 2. Identify expertise and/or third party businesses in both countries to take on the design and execution of drug development, including manufacturing, preclinical and clinical studies for individual projects 3. Identify expertise and /or third party businesses in both countries to take on the design and execution of the development of devices and diagnostics 4. In order to fund development of these projects, establish clear guidelines and criteria to rapidly fund innovative projects: • Evaluation team for each area • Team to develop strategy/plan to proof of concept or value creation point that meets all industry standards • Develop a business strategy and timelines for program to advance, recruit investment and potential partnerships • Develop a competitive analysis for the program and criteria for development to meet market needs • Team to evaluate progress and discontinue funding if criteria are not met or changes in competitive environment no longer makes the investment worthy. 5. Establish a fund or budget for funding innovation alone or in partnership with industry/investors MALKA COHEN-ARMON ILANA GOZES Tel-Aviv University PI: Prof. M. Cohen-Armon, D.Sc. Dept. of Physiology & Pharmacology and Neufeld Cardiac Research Institute, Sackler School of Medicine, [email protected] Co-PI: Prof. I. Gozes. Ph.D. Dept. of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Editor-in-Chief, Journal of Molecular Neuroscience and Chief Scientific Officer Allon Therapeutics Inc. www.allontherapeutics.com Topic: Mechanisms and Therapy, including cell therapy Subjects of Interest: Molecular mechanisms underlying long-term memory formation Exclusive erasure of memories by PARP inhibitors (frightening or compulsive memories) Core technology: Biochemical pharmacological and cell biology methods. Signal transduction mechanisms targeting gene expression PARP proteins and chromatin remodeling Collaboration with Inotek Inc., MA, USA. Major accomplishments: Discovery of signal transduction mechanisms underlying long-term memory formation Relevant references • Long-term memory requires polyADP-ribosylation. Cohen-Armon et al., Science 2004, 304: 1820-1823 • PolyADP-ribosylation is involved in neurotrophic activity. Visochek et al., J. Neurosci. 2005, 25:7420-7428. • DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: A link to histone acetylation. Cohen-Armon et al., Mol. Cell 2007, 25: 297-308 • PARP-1 activation in the ERK signaling pathway. Cohen-Armon M., Trends In Pharmacol. Sci. 2007, 28: 556-560 • PolyADP-ribosylation is required for long-term memory formation in mammals. Goldberg et al. J. Neurochem. 2009, 111:72-79 Existing partnership between Israel and Canada: None Suggestions for mode of collaboration: Consortium DANIEL GOLDOWITZ Name: Daniel Goldowitz NeuroDevNet, Centre for Molecular Medicine and Therapeutics, Children Family Research Inst., Dept Medical Genetics, UBC Contact: 604-875-3822, [email protected] • Topic: Mechanisms and Therapy, including cell therapy • Brain Development • Animal models, gene expression, clinical studies in Autism, Cerebral Palsy, and Fetal Alcohol Spectrum Disorder • NeuroDevNet is the first trans-Canadian Network that is focused on Brain Development • Ilan Golani, Nissim Ben-Arie, Michal Begin • There are excellent researchers and potential companies engaged in issues related to brain development that could be catalyzed toward action through this initial meeting. EREZ LEVANON • Mechanisms and Therapy, including cell therapy • • • Subject of interest : RNA editing in the brain Core technology: global screen for RNA editing About the group and major accomplishments: • • 3 postdocs, 4 PhD Students Large scale Identification of editing in human (Levanon at el, Nature biotechnology 2004) Genomic screen for editing sites (Li*, Levanon* at el ;Science 2009) Editing in primate (Paz, Levanon at el ; PNAS 2010) Editing in aging (Nicholas at el Mech Ageing Dev. 2010) Existing partnership between Israel and Canadna -none Suggestions for mode of collaboration: -consortium?… A to I RNA editing • RNA editing is a post-transcriptional change in the RNA sequence Adenosine is converted by ADAR protain into inosine- and read as Guanosine. • RNA editing is essential, Altered editing patterns were found in brain related diseases. • Editing lead to complexity of the human brain transcriptome • A-to-I RNA editing is common in human and usually primate specific Glutamate receptor Serotonin receptor Screen for RNA editing by padlock Target Capturing technology pol lig feature 1 feature 2 PCR Illumina) Li*, Levanon* et al . Science 2009 Editing examples E>G Ca2+-dependent secretion activator (CADPS) Editing rescues a stop codon (UAG) into tryptophan (UGG). Adding 29 amino acids to the protein amyloid beta A4 precursor protein-binding MOSHE SZYF Name: Moshe Szyf McGill University Montreal Canada Contact: 514-398-7107 [email protected] • • • • Topic: Mechanism and Therapy Subject of interest: Epigenetic therapeutics in mental health Core technology: Epigenetics pharmacology and biochemistry About the group and major accomplishments: Discovery of behavioral epigenetics and discovery of DNA methylation as a therapeutic target and developing of DNA methylation pharmacology • Existing partnership between Israel and Canada; to be determined. • Suggestions for mode of collaboration: pharmaceutical spinoff collaboration for developing epigenetic drugs for mental health Epigenetic pharmacology reverses epigenetic programming of behavior MICHAEL S. KOBOR Name: Michael S. Kobor Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, Department of Medical Genetics, University of British Columbia NeuroDevNet NCE & AllerGen NCE; Scholar Canadian Institute for Advanced Research Contact: 604 875-‐3803; [email protected] • • Topic: Mechanisms and Therapy, including cell therapy Subject: Epigenetics in human health and disease – – • • Core technology: High throughput quantitative measurements for epigenetic Major accomplishments: – – – – – • • Fetal alcohol syndrome, early brain and biological development, neurodegenerative disorder, healthy aging and age‐related diseases Discovery two key enzymes involved in epigenetic regulation and gene expression Revealed mechanisms for early-‐life environments such as poverty and parental stress “get under the skin” to affect health across life-‐span Established with Michael Hayden and Max Cynader the “Genetics and Epigenetics Centre” of the Canadian Longitudinal Study of Aging Existing partnership between Israel and Canada: None as of yet Suggestions for mode of collaboration: Israel-‐Canada consortium for population and disease cohorts with joint and coordinated measures, interfacing with companies focused on technology development and biomarker discovery GERSHON GOLOMB Gershon Golomb School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem [email protected] http://research.ekmd.huji.ac.il/researchers.asp?id=268#page_211 Topic: “Mechanisms and Therapy, including cell therapy” Canadian Collaborators M. Griffith, Ottawa Eye Institute, Ottawa Hosp. F. Gu, Institute of Nanotechnology, U. Waterloo Ongoing Research Topics • Anti-inflammatory effects by nanoparticles of bisphosphonates. • Nanoparticles of antisense and siRNA in mammary carcinoma. • Immunomodulation by nanoparticles. • Targeted nanoparticles in cancer therapy. 50 nm 100 nm BBB Transport by Nanoparticles Exploiting the Innate - Immunity System (TransBrain) • The brain is under immunological surveillance – Increased BBB passage of monocytes/neutrophils • brain-associated inflammatory disorders (multiple sclerosis, Alzheimer's disease, Cancer, TBI and more) • Specific liposomes and polymeric NP are phagocytized by circulating monocytes – discharge their encapsulated drug in the brain tissues. ILLANA GOZES • • • • • • Topic: Mechanisms and Therapy Subject of interest: Neuroprotection, nerve cell skeleton and transport system, learning, memory, motor function, neurodevelopment, neurodegenerative and neuropsychiatric diseases Core technology: Neuroprotective proteins About the group and major accomplishments: Discovery of neuroportective genes and drug candidates preclinical discovery team (TAU)– davunetide in phase II/III clinical trials in progressive supranuclear Palsy (PSP), a Parkinson-like syndrome (Allon) Existing partnership Israel and Canada: TAU (Ramot) and Allon. Suggestions for mode of collaboration: Consortium - TAU Center for Neurodevelopment, Neurodegeneration, Neuroprotection: deciphering mechanisms + cell/animal/ high throughput and proof of concept testing facilities concentrating on Israeli/Canadian innovations. Fundamental Mechanism of Action Microtubules Essential for neuronal structure and function Neurodegeneration Destabilization and breakdown of microtubules Progressive loss of function Tau hyperphosphrylation Leads to cell death Neuroprotection Recent reviews Gozes et al., Curr Alzheimer Res. 2009; 6:455-60. Morimoto et al., Chimica Oggi / Chemistry Today. 2009; 27: 16-20. Gozes I., Curr Alzheimer Res 7:685-696, 2010 Gozes I. Curr Pharm Des 17:1040-1044, 2011 NAP (davunetide) crosses the blood brain barrier Stabilizes and repairs microtubules Reduces Tau hyperphosphrylation Restores neuronal structure and function 53 GAVISH MOSHE VEENMAN LEO PAPADOPOULOS VASSILIOS • Topic (Mechanisms and therapies, including cell therapy ) • Subject of interest (drug development against neurodegeneration) • Core technology (Synthesis of specific quinazolines, assays of cell viability and related processes in cell culture, assays of cell death of glia and neurons in animal models) • About the group and major accomplishments We study the role of the mitochondrial 18 kDa Translocator Protein (TSPO) in mechanisms related to cell death. We have developed ligands for the TSPO that prevent cell death otherwise induced by the TSPO in cell culture and animal models. • Existing partnership between Israel and Canada We have published several articles together regarding TSPO function. • Suggestions for mode of collaboration (for example consortium) Bilateral partnership for testing of drugs developed by the partners. The synthetic TSPO ligand MGV-1 protects astrocytes in the amygdala and the pyriform cortex A) KA + vehicle C) KA + MGV1 treatment B) KA + Vehicle D) vehicle + vehicle (control) Gavish Moshe, Veenman Leo, Papadopoulos Vassilios URI WORMSER Uri Wormser Institute of Drug Research The Hebrew University [email protected] Topic: Mechanisms and Therapy, including cell therapy Subject of Interest: Development of peptides for autoimmune diseases Core Technology: a) Development of peptides for treatment of multiple sclerosis Effect of orally administered IIIM1 (H2A fragment) in the rat model 4 Neurological score Neurological score Effect of orally administered IIIM1 (H2A fragment) in the mouse model 3 2 1 * 0 6 10 * 14 * * 18 * 22 Time (d) after immunization 3 2 1 * * * * * 0 8 12 16 20 24 28 Time (d) after immunization Effect of orally administered Japanese rice extract in the mouse model Effect of ip injected RA1 (Japanese rice peptide) in the mouse model 4 4 1 * * * * * Neurological score RA1 Neurological score Neurological score Oryza Japonica extract 2 0 3 control control 3 Effect of orally administered RA1 (Japanese rice peptide) in the mouse model 3 2 1 * * * * * 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (d) after immunization 2 1 0 0 control RA1 * * * * * 0 2 4 6 8 10 12 14 16 18 20 22 24 26 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (d) after immunization Time (d) after immunization b) Development of peptides for treatment of systemic lupus erythematosus 100 Control IIIM1 75 50 25 * * * 0 0 4 8 12 16 20 24 28 Urinary protein (mg/dl) Proteinuria (mg/dl) 125 Relevant publications of our group Effect of 1g/kg UBE (antitrypsin fragment) in lupus model Effect of IIIM1 in lupus model 200 control UBE 150 100 50 * 0 1 4 * ** ** ** 7 10 13 16 19 22 25 28 Days of treatment Treatment period (days) •Brodsky, B. et al.Toxicol. Appl. Pharmacol. 229(3), 342-350 (2008). •Shapira, E et al. J. Autoimmun. 35, 98-106 (2010) . •Finkelstein, Y et al. Neurotoxicology, 31(5), 608-620 (2010). •Shapira, E., et al. Lupus 20(5), 463-472 (2011). •Schussheim, Y., et al. Peptides, 32(1), 125130 (2011). NAPHTALI SAVION Topic: Mechanisms and Therapy, including cell therapy Subject: Antioxidant for the treatment of neuro-degenerative diseases – Autism; MS; Rational: Autism and MS are associated with low reserves of glutathione (GSH) and increase susceptibility to oxidative stress Molecule: Allylmercapto-N-Acetyl-Cysteine (ASSNAC) Mechanism: ASSNAC slowly attacks free sulfhydryls by the thiol-disulfide exchange reaction, resulting in NRF2 mediated increased expression of phase II detoxifying enzymes; Effects: Elevation of GSH level by multiple mechanisms: (I) (II) (III) up-regulation of GCLM expression (GSH synthesis) supply of cysteine in the form of N-Acetyl-Cysteine (NAC) up-regulation of cystine transporter (xCT). Preliminary results: • ASSNAC significantly elevates GSH level in endothelial and nerve derived cell lines and protects these cells from oxidative stress • Treatment of experimental autoimmune encephalomyelitis (EAE) mouse model with ASSNAC (50 mg/kg/day) significantly increases brain GSH level and attenuates the disease clinical symptoms Accomplishments: • • • Patent on eye drops - licensed to Tubilux, Italy product on market: Lipimix Patent on platelet function test – co-founder of Matis Medical product on market: Impact-R Chief Scientific Consultant and R&D service to ColBar Lifesiences products on market: Ossix and Evolence Mode of collaboration: Joint R&D; License agreement; DANIEL SEGAL • Topic: Therapy • Subject of interest: Amyloidogenic diseases. • Core technology: Design and synthesis of novel small molecules; testing them in vitro, in fruit-flies, in mice. • About the group: Collaborating with protein chemistry lab of Ehud Gazit, and mouse neurobiology lab of Dan Frenkel. • Major accomplishments: Demonstrated efficacy and lack of toxicity of novel naphthoquinones, peptidomimetics and cinnamon extracts in inhibiting toxic amyloids in Alzheimer’s and Parkinson’s disease. • Existing partnership between Israel and Canada: None. • Suggestions for mode of collaboration: Partnering with academia/Biotech on drug development and preclinical/clinical testing. MOUSSA B.H. YOUDIM ORLY WEINREB ET & NPF The Canada-Israel Technology Innovation Partnering Event, Tel Aviv 06 July, 2011 Mechanisms and Therapy; Neuroprotective-Neurorescue Drugs for Alzheimer’s disease Moussa B.H. Youdim and Orly Weinreb Eve Topf Center of Excellence for Neurodegenerative Diseases Research Technion-Faculty of Medicine, Israel Eve Topf Center is studying the cascades of molecular and neurochemical mechanisms involved in the process of neurodegeneration in Alzheimer's, Parkinson's and Amyotrophic lateral sclerosis diseases, as well as their cellular and animal models by employing transcriptomic and proteomic profiling. The ultimate goal is to develop novel neuroprotective and neurorestorative drugs with disease modifying activity as multi-target compounds. (Youdim et al., Trends Pharmacol Sci 2005;26:27-35). ET & NPF The Canada-Israel Technology Innovation Partnering Event, Tel Aviv 06 July, 2011 Mechanisms and Therapy; Neuroprotective-Neurorescue Drugs for Alzheimer’s disease Moussa B.H. Youdim and Orly Weinreb Eve Topf Center of Excellence for Neurodegenerative Diseases Research Technion-Faculty of Medicine, Israel (e-mails: [email protected]; [email protected]; Tel:+972-48295291) Eve Topf Center is studying the cascades of molecular and neurochemical mechanisms involved in the process of neurodegeneration in Alzheimer's, Parkinson's and Amyotrophic lateral sclerosis diseases, as well as their cellular and animal models by employing transcriptomic and proteomic profiling. The ultimate goal is to develop novel neuroprotective and neurorestorative drugs with disease modifying activity as multi-target compounds. (Youdim et al., Trends Pharmacol Sci 2005;26:27-35). Neuroprotective-Neurorescue Drugs for Alzheimer’s disease So far, we have discovered and developed the anti-Parkinsonian drug Azilect® (rasagiline; Teva Co. Israel) and multi-target drugs ladostigil (TVP3326), now in Phase IIb control clinical studies in Alzheimer's disease (AD), and in cooperation with company Varinel Inc. (West Chester, PA, USA) the novel neuroprotective-neurorestorative the iron chelating M30 series. M30 was designed from the prototype iron chelator, VK28 (5-[4-(2- hydroxyethyl) piperazine-1ylmethyl]-quinoline-8-ol) (Varinel Inc. USA) and enriched with the propargyl moiety of the antiParkinson's MAO-B inhibitor, rasagiline and thus, inherited some of their neuroprotective and neurorestorative properties ( Zheng et al., J Pept Res 2005;66:190-203). M30 is a selective iron-chelating and free radical scavenging core structure, which is associated with inhibition of lipid peroxidation and membrane damage, as well as a unique potent and brain selective inhibitory activity directed against both monoamine oxidase (MAO)-A and -B, thereby increasing brain levels of dopamine, serotonin and noradrenalin (Weinreb et al., Neurotherapeutics. 2009;6(1):163-74). M30 possesses neuroprotective/neurorestorative activities against N-methy-4-phenyl-1,2,3,6tetrahydropyridine (MPTP)- and the the proteasome inhibitor, lactacystin- induced neurotoxicity in mice, similar to those of the rasagiline, the latter properties associated with the propargylamine moiety (Gal et al., J Neurochem 2005;95:79-88; Zhu W. et al., 2007 Faseb J 21, 3835-44). Recently, we have demonstrated that M30 involved in the regulation of the Alzheimer's amyloid precursor protein (APP) levels/processing in neuronal cells cultures models of AD, and attenuated cerebral A pathology and behavioral deficits in the APP/Presenilin 1 (PS1) double transgenic mice model of AD (Avramovich-Tirosh et al., J Neurochem 2007;100:490-502; Kupershmidt et al., Fasbe J. Submitted ). AMIRAM GOLDBLUM (HANNA ROSENMANN) The Hebrew University of Jerusalem Institute for Drug Research Molecular Modeling and Drug Design Lab Contact: Amiram Goldblum [email protected] +972-544-653292 • • • • • Topic: Mechanisms and Therapy in Alzheimer’s Disease Subject of interest: Multitargeted inhibition of beta and gamma Secretases Core technology: In Silico, Computational, Prize winning algorithm (generic algorithm) About the group and major accomplishments:The Goldblum Group developed the top optimization algorithm called “Iterative Stochastic Elimination” (ISE), used for finding “many needles in a haystack” – achieving unprecedented enrichmetns in several drug discovery campaigns: acetylcholinesterase inhibitors, Bcr-Abl oligomerization inhibition, Differential cytoctoxicity to colon cancer cells vs. normal human and more Suggestions for mode of collaboration: Need for Organic Synthesis counterparts and Analytical and Pharmaceutical Chemistry for measuring molecular properties in pharmacokinetic relevant models The Hadassah Hebrew University Medical Center, Jerusalem Department of Neurology, The Agnes Ginges center for Human Neurogenetics Laboratory of Neurogenetics Contact: Hanna Rosenmann [email protected] +972-505-172295 • • Topic: Mechanisms and Therapy in Alzheimer’s Disease Subject of interest: Multitargeted inhibition of beta and gamma secretases • • • Core technology: Neuronal cell and animal models for Alzheimer’s disease (biochemical, immunological, pathological and behavioral studies) About the group and major accomplishments: The Rosenmann Group generated novel animal models for Alzheimer’s disease (using transgenic, environmental and immunological approaches), and investigated the effect of environmental risk factors on Alzheimer’s related tangle pathology. This group developed new therapeutic approaches, such as tau immunotherapy. The Laboratory of Molecular Neurogenetics, headed by Hanna Rosenmann, serves as a National Center for Molecular Genetic Diagnosis and CSF Biomarker Analysis Suggestions for mode of collaboration: Further validating of effective molecules (which reduce amyloid levels and secretase activities) in cell and animal models ALEX KOZAK Dr. Alex Kozak, CEO & President [email protected] D-PHARM LTD. D-Pharm Ltd. 2011 Overview 73 Brief Summary • Topic: Mechanisms and Therapy • Main Interests: Innovative medicine for treatment of neurodegenerative diseases • Core technology: Membrane Active 2+ 2+ 2+ Chelators (MAC) of Zn , Ca , Cu ions D-Pharm Ltd. 2011 Overview 74 Brief Summary • Key achievement: Introduction of First in class Broad-Spectrum Neuroprotective drugs: – DP-b99: Phase III in Acute Stroke – Preclinical products in Dementias & ALS • Canadian partner: The Canadian Stroke Consortium • Collaboration strategy: One-to-One and/or in Consortium D-Pharm Ltd. 2011 Overview 75 IMRIC, Hebrew University-Hadassah School of Medicine Ronit Sharon PhD Email: [email protected]; tel: 972 2 675 8170 •Topic: Mechanisms of therapy •Subject of interest: neurodegenerations, Parkinson’s disease •Core technology: purification and analyses of proteins, molecular and cellular biology, neuropathology •About the group: We are interested in biochemical, molecular and cell biology aspects of neuronal degeneration during aging of the mammalian brain, in particular, Parkinson’s diseases and the related synucleinopathies. We perform extensive studies related to the trafficking, processing and secretion of alpha synuclein (a-Syn), a protein critically implicated in the pathogenesis of Parkinson’s disease and the synucleinopathies. We have discovered that a-Syn normally occurs in oligomeric forms and interacts with certain brain lipids. We have further shown that these oligomeric forms progressively accumulate into Lewy bodies, the prototype pathogenic insults, when neuronal lipid metabolism is altered. To follow on these findings, we now seek the identification and control of the specific metabolic pathway involved in a-Syn toxicity, focusing on specific pathways of gene regulation, for the development a therapy for Parkinson’s disease. •Existing partnerships with Canada: none •Mode of collaboration: a consortium SHAI RAHIMIPOUR • Topic Mechanisms and therapies, including cell therapy • Subject of interest Multiple Sclerosis (MS) Alzheimer’s Disease (AD) • Core technology Nano-sized self-assembled neuroprotecting peptides (MS, AD) Targeted protein microspheres for Amyloid beta clearance (AD) • About the group and major accomplishments 2 Research Associates 2 Ph.D. Students 4 MSc. Students • About the group and major accomplishments Development of combinatorial and HTS methods for discovery of neuroprotecting self-assembled unnatural peptides Discovery of nano-sized peptides with potent in vitro anti-inflammatory and neuroprotecting activity Potent protecting activity in EAE mice model of MS Development of a novel method to generate surface modified protein microspheres Discovery of microspheres that can selectively bind amyloid beta, inhibit its aggregation and reduce its toxicity to neurons Discovery of microspheres that enhance the phagocytosis of amyloid beta for better clearance • Suggestions for mode of collaboration (for example consortium) Establishment a medium size consortium to study the effect of the nano-sized peptides and microspheres in related animal models toward preclinical studies. DAN T MAJOR • • Topic: Mechanism and Therapy, including cell therapy Subject of interest: Enzyme mechanisms and rational drug design using molecular modeling tools Core technology: Cutting-edge methodologies for molecular modeling including • – – – – • Expertise in physical basis for enzyme catalysis and molecular recognition In-depth modeling tools (quantum/classical simulation software platforms) Large-scale in-silico drug design tools (protein modeling, docking, screening) Long experience in racemase enzymes (e.g. Serine racemase – NMDAdependent pathological conditions including Alzheimer’s disease, amyotrophic lateral sclerosis, and schizophrenia) About the group and major accomplishments: The Major group is a theoretical group involved in modeling of biological systems as well as nanotechnology systems. – – – – Group has 10 members (3 post-docs, 2 Ph.D., 5 M.Sc.) PI is Alon fellow (MOS), Krill prize 2010 (Wolf foundation) 18 publications in first 3.5 years at BIU (PNAS, JACS [×3]) Equipment: Computer cluster of 236 computing cores HANOCH SENDEROWITZ Structure/ Sequence Structure-based Modeling Virtual Library Ligand-based Modeling Screening Known Ligands Mechanism and Therapy • Target independent Virtual Hits Scoring • Data dependent • Virtual screening Binding Assays Leads 3D Optimization In silico Chemistry Biology Drug Candidate • Molecular simulations • QSAR/QSPR • Computational ADME The group • One post-doc • One Ph.D. student • Six master students • Multiple software tools • Medium size computational cluster R516 R1070 Y563 F1068 • Open to suggestions about nature of the collaboration LAURENT BENISVY ARIE GRUZMAN • • • • Topic : Mechanisms and therapies, including cell therapy Subject of interest: Potential drugs for neurodegenerative diseases Core technology: Organic synthesis / in vitro cell experiments About the group and major accomplishments: New project (2 years) Work submitted to Angewandte Chemie • • - Existing partnership between Israel and Canada: No Suggestions for mode of collaboration: In vivo experiments/ BBB crossing experiments Topic: Novel synthetic chemical chaperones as a basis for ALS (Amyotrophic Lateral Sclerosis) treatment. Subject of interest: Design and Synthesis of New anti-ALS Therapeutics Agents. Core technology: In our search for small molecules that can prevent the formation of toxic misfolding proteins and aggregates, we have synthesized chemical chaperons that primarily targeting cell organelles and areas where ALS –related proteins are aggregating (ER, lysosomes and mitochondria). Refolding by chemical chaperons will enable lysosome proteolytic enzymes and the proteosome system to cleave the misfolded proteins properly and decrease ALS progression. My group: My scientific group has expertise in following fields: organic synthesis, analytical chemistry, pharmacology, pharmacokinetic and biochemistry. Preliminary results of our work was published at 2007: Gruzman A, et al. A common molecular signature in SOD1 for both Sporadic and Familial Amyotrophic Lateral Sclerosis. Proc Natl Acad Sci U S A 2007, 104, 12524-12529. Existing partnership between Israel and Canada: We do not have yet a partnerships with Canadian scientists. ARIE GRUZMAN Topic: Novel synthetic chemical chaperones as a basis for ALS (Amyotrophic Lateral Sclerosis) treatment. Subject of interest: Design and Synthesis of New anti-ALS Therapeutics Agents. Core technology: In our search for small molecules that can prevent the formation of toxic misfolding proteins and aggregates, we have synthesized chemical chaperons that primarily targeting cell organelles and areas where ALS –related proteins are aggregating (ER, lysosomes and mitochondria). Refolding by chemical chaperons will enable lysosome proteolytic enzymes and the proteosome system to cleave the misfolded proteins properly and decrease ALS progression. My group: My scientific group has expertise in following fields: organic synthesis, analytical chemistry, pharmacology, pharmacokinetic and biochemistry. Preliminary results of our work was published at 2007: Gruzman A, et al. A common molecular signature in SOD1 for both Sporadic and Familial Amyotrophic Lateral Sclerosis. Proc Natl Acad Sci U S A 2007, 104, 12524-12529. Existing partnership between Israel and Canada: We do not have yet a partnerships with Canadian scientists. Suggestions for mode of collaboration: We are looking for cooperation with Canadian biologists for in vitro and in vivo studies. In particular: 1. Validation of the mechanism of the action of novel chemical chaperones. 2. Testing of the effective in vitro compounds in ALS mice models (mice motor functions, motor neurons survival, tissue morphology changes, and life span) 3. Optimization of the pharmacokinetic parameters of active in vivo compounds to improve its bioavailability, oral activity, biodegradation, transmembrane permeability, potency, and efficacy. Chemical chaperones [wtSOD1]damaged mSOD1 or others misfolded proteins [wtSOD1]damaged mSOD1 or others misfolded proteins Accumulation of toxic SOD-1 species Aggregation Motor neuron death Proteolytic enzymes Degradation Cell survival Accumulation of toxic SOD-1 species Aggregation Motor neuron death Degradation Cell survival The final aim of the project is to develop a lead compound that is active in vivo with a known mechanism of action and improved pharmacokinetic parameters. Such a compound should be used in clinical trials in the next stage of this drug design project. JULIA SHIFMAN Technology: design of protein-protein interactions • Subject of interest: design of calmodulinbased sensors and biomarkers Past accomplishments: • – -- design of calmodulin molecules with high specificity and affinity to one target protein, e.g CaMKII Yosef et al, JMB 2009 design of Ca-deficient CaMs Shifman et al, PNAS 2006 CaMKII Present collaborators: Prof. Kevin Truong, • CaN Department of Electrical Engineering, University of Toronto – design of switches and sensors based on Ca-binding proteins. JACOB GOLENSER Jacob Golenser The Hebrew University of Jerusalem The Kuvin Centre for the Study of Infectious and Tropical Diseases Tel. 972 2 6758090, Email: [email protected] Topic: Mechanisms and Therapy Subject: Cerebral malaria Major accomplishments: Proof of concept Technology: Immunomodulation, Slow drug delivery Collaboration: Initially- research Cerebral Malaria is the most severe complication of P. falciparum infection Trophozoites depict ligands (e.g. histidine-rich proteins in knobs) Sequestration Knobs A section of brain taken from a patient with cerebral malaria. Parasitized red blood cells within capillary Activation of endothelial cells by plasmodial and immune components Impaired BBB function Plasma influx to CNS Angiogenic dysregulation Th1 responses Brain edema and neurological impairment Rate of cerebral malaria after steroid treatment Methylprednisolone hemisuccinate[a] β-methasone hemisuccinate[b] Control 80% 90% Free drug 90% 67% Liposomal drug 65% 18% Mice were treated on days 3, 5, 7, and 9 post-infection with [a] 10mg/kg/d methylprednisolone hemisuccinate, or [b] 20mg/kg/d β-methasone hemisuccinate, by i.v. injection. Disease pattern in PbA-infected C57BL/6 mice treated with artesunate or artemisone twice a day, on days 7-9 post inoculation Infection outcome Compound Dose Cerebral malaria Anemic malaria Cured 20µl 4/8 4/8 0/8 2x2.5 mg/kg/d 6/8 2/8 0/8 2x5 mg/kg/d 1/8* 7/8* 0/8 2x2.5 mg/kg/d 0/8* 3/8 5/8*† 2x5 mg/kg/d 0/8* 0/8*† 8/8*† DMSO Artesunate Artemisone *Significant vs. control. †Significant vs. artesunate. NOAM SOBEL YEHUDAH ROTH SAGIT SHUSHAN Prof Noam Sobel, Neurobiology, Weizmann Institute of Science Dr Yehudah Roth, Otolaryngology, Wolfson Medical Center, TAU Dr Sagit Shushan, Otolaryngology, Wolfson Medical Center, TAU & Neurobiology, Weizmann Institute of Science [email protected] +972-546685688 [email protected] +972-544832075 Session: "Mechanisms and Therapy “ The nose as a diagnostic gateway to the brain Olfactory research using fMRI and direct electrical and optical monitoring of the olfactory epithelium in humans Olfactory cleft surgery - sampling and intervention, including development and testing of novel endoscopy and surgical tools Rehabilitation in olfactory disorders (i.e. head trauma) using behavioral and surgical interventions Brain monitoring of neurodegenerative disorders using the nose as a diagnostic gateway. Behavioral Neurology and Otolaryngology relationships, novel concepts of diagnosis and therapy approaches Prof Noam Sobel, Neurobiology, Weizmann Institute of Science Dr Yehudah Roth, Otolaryngology, Wolfson Medical Center, TAU Dr Sagit Shushan, Otolaryngology, Wolfson Medical Center, TAU & Neurobiology, Weizmann Institute of Science [email protected] +972-546685688 [email protected] +972-544832075 Session: "Mechanisms and Therapy “ Sniff-controlled devices to assist the disabled YOAV MEDAN EYAL ZADICARIO InSightec, Nahum Heth 5 Tirat, Carmel, Israel Yoav Medan PhD, [email protected] Eyal Zadicario, [email protected] • Neurostimulation & Neurotechnologies • Translational Research into Clinical Applications and Clinical Studies in Neuro Therapy • Non-invasive focused ultrasound treatments under MR guidance • In last 12 years InSightec achieved; – First MR guided Focused Ultrasound Surgery system accepted and approved as non-invasive therapy in specific body applications – Novel un matched technology for transcranial non-invasive focused ultrasound technology. – 5 Clinical Studies approved (FDA/Health Canada) for brain tumors and functional disorders (Essential Tremor) – More than 20 patient treated in on-going clinical trials to date • Potential Research include: – Clinical studies in functional disorders [PD,ET,epilpesy] – Brain Tumors – Stroke – Targeted Drug Delivery – Non-Invasive Neurostimulation Projects • Existing partnership between Israel and Canada includes 2 clinical sites in Toronto university for prostate and brain research. • Collaboration such as: Consortium partnerships, Business collaboration, Additional research centers for translational and clinical research. ITSCHAK LAMENSDORF • Topic: Mechanisms and Therapy, including cell therapy • Subject of interest: Development of relevant models for unmet needs in neurodegenerative diseases and translational tools for early stage development from discovery to first in patient Core technology: Pharmaseed is a preclinical CRO that has a unique know-how in integrating relevant experimental readout in CNS pre-clinical animal models (in vitro and in vivo) in order to asses efficacy and safety. About the group and major accomplishments: PharmaSeed is a Research -Oriented CRO with More than 50% PhD Level Personnel. Key Personnel with an average 10 years of experience working in management positions in innovative companies. Existing partnership between Israel and Canadna None. Suggestions for mode of collaboration: Pharmaseed is interested in the development of experimental models that will integrate translational validated tools in order to integrate them into discovery early pre-clinical stage. These will be instrumental in evaluating response and kinetics via development of PK-PD models that are based on allometric (dose-translational) conversion linked to a “coefficient” of biological-response parameters. In addition, studying disease progress in correlation with biochemical / genomic biomarkers in animal models (e.g. induction of PD in diabetic / aged or obese animals) should provide additional understanding as to personalization of therapy. We would also like to include “generic” drug phenotype screening that is based on behavioral outcome as a tool for drug screening. Development of such tools could be integrated in any targeted CNS disease developmental program as a unique tool for assessment of potential clinical efficacy. To achieve this goal Pharmaseed wishes to collaborate and form partnership with pharmaceutical companies or academic Institutes having the same goal. MICHAL ROLL One stop shop for translational R&D activities of 1100 physicians, 60 PhD researchers and their research staff Interdisciplinary research centers in brain research (focus on advanced imaging), embryonic and adult stem cells, hospital infections, movement disorders of the elderly, neurodegenerative diseases, metabolic diseases, genetic basis of diseases About 2000 on going clinical trials ( expert internationally registered IRB, in house auditing, contracts) Dedicated Early phase clinical trial facility In house Incubator for Medical Devices dedicated research facilities, IP consulting & registering Technology Transfer - licensing of Technology Dedicated labs – cancer research, GI diseases, Brain imaging research lab (3 TESLA MRI) Genomics and bioinform atics lab Gait assessment lab Cell therapy with GMP facility New animal facility for small animals 113 Neurosurgery at TASMC - Comparative Statistics Total neurosurgical cases per year - 2600 ▪ It is about 40% of cases done in Israel ▪ ▪ ▪ We do about: – 60% of malignant brain tumor cases in Israel; – 90% of epilepsy surgery cases; – 40% of pediatric neurosurgery cases (~ 400 cases/year at TASMC) – 70% of interventional neuroradiology cases (300). – 90% of peripheral nerve cases. 85% of fMRI (fMRI DTI) examinations (150 /year) 114 TASMC Applied Neuroscience Center The Mission Improved healing of the brain by Prevention of disease & Restoration of function The vision ▪ ▪ ▪ Synergism – Collaborative clinical & research efforts Multi-Level – Neuron to brain, genes to behavior Applied – Rapid translation from Lab-bench to patient-care 115 World leading labs with large scale projects ▪ Neurophysiology (kinematics of gait, cognition) ▪ Neuro genetics ( genotypes, polymorphism, neurofibromatosis) ▪ Advanced brain imaging (fMRI/EEG, DTI, MRS, PET/CT, infant imaging) World leading clinicians in brain medicine ▪ Neurosurgery (Adult, Pediatric, Functional) ▪ Neurology (e.g. Stroke, Parkinson, Epilepsy, ALS, MS) ▪ Neuroimaging (e.g. Presurgical brain mapping) Collaboration between 1&2 is implemented continuously Cutting edge combined technologies on premise ▪ Non-invasive: in-vivo imaging (EEG fMRI), TMS, gait assessment ▪ Invasive: intracranial / deep brain recording and stimulation, neurchemical mapping (PET/CT). Access to unique populations for research ▪ Ethnic genetic mutations (Ashkenazi Jews, Arabs), Stressful Life Events (mandatory military service, wars), Immigrants (Ethiopians, Russians) 116 International Collaborations Newcastle University Oxford University, Oxford Katholieke University, Leuven St. George University, London Radboud University, Nijmegen Columbia University, New York Beth Israel, New York Groningen University, Groningen Harvard Medical School, Boston Einstein Medical School, New York Spaulding Rehabilitation Institute, Boston University Pierre & Marie Curie, Paris Max Planck Institute, Leipzig University of Dresden, Dresden Charite University, Berlin University Autonoma, Barcelona University of Genoa, Genoa University of Bologna, Bologna University of Sassari, Sardinia Major international competitive non profit sources for research NIH NCI - Radiation Therapy Oncology Group (RTOG) ALS Assoc. NASRAD - brain and behavior research fund 117 MacDonnell Foundation National Parkinson Foundation MJ Fox Foundation European Union research programs European Union research programs March of Dimes Fragile X Foundation DOD - US army Michal (Micki) Roll, PhD, MBA Director, R & D Division, Tel-Aviv Sourasky Medical Center • PhD in Pharmacology, Hebrew University • Post Doc in Neurobiology • MBA Leicester University, UK •In charge of all research affairs – grants, clinical trials, IP (patents) and technology transfer. [email protected] www.tasmc.org.il